Key Points
- CEO Chad Robins sold 278,676 Adaptive Biotechnologies shares for approximately $6.82 million at an average price of $24.48, reducing his direct stake by 11.33% to 2.18 million shares.
- Adaptive Biotechnologies reported quarterly revenue of $71.55 million, up 21.5% year over year and above estimates, but its $0.25 per-share loss was wider than expected.
- Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $24.42; institutional investors own 99.17% of the company.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) Director Peter Neupert sold 124,690 shares of the business's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.15, for a total transaction of $3,135,953.50. Following the completion of the transaction, the director directly owned 130,625 shares of the company's stock, valued at approximately $3,285,218.75. This represents a 48.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Adaptive Biotechnologies Stock Performance
Adaptive Biotechnologies stock opened at $25.49 on Thursday. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16. The company's 50-day moving average is $21.75 and its two-hundred day moving average is $17.24. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The company has a market cap of $4.07 billion, a PE ratio of -62.17 and a beta of 2.08.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same period last year, the company earned ($0.17) earnings per share. The business's revenue was up 21.5% compared to the same quarter last year. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the company. BTIG Research boosted their target price on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. TD Cowen boosted their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Morgan Stanley increased their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, May 6th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Adaptive Biotechnologies currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.42.
View Our Latest Report on Adaptive Biotechnologies
Hedge Funds Weigh In On Adaptive Biotechnologies
A number of large investors have recently modified their holdings of ADPT. 1492 Capital Management LLC bought a new stake in Adaptive Biotechnologies during the fourth quarter worth about $1,484,000. Jupiter Asset Management Ltd. grew its stake in Adaptive Biotechnologies by 33.8% in the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company's stock valued at $5,892,000 after purchasing an additional 91,683 shares in the last quarter. Rhenman & Partners Asset Management AB increased its position in shares of Adaptive Biotechnologies by 22.2% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company's stock worth $9,825,000 after purchasing an additional 110,000 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $65,942,000. Finally, Jennison Associates LLC boosted its holdings in shares of Adaptive Biotechnologies by 103.9% in the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company's stock valued at $43,437,000 after buying an additional 1,363,181 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
